HUE067445T2 - Mirikizumab fekélyes vastagbélgyulladás kezelésében - Google Patents

Mirikizumab fekélyes vastagbélgyulladás kezelésében

Info

Publication number
HUE067445T2
HUE067445T2 HUE19722256A HUE19722256A HUE067445T2 HU E067445 T2 HUE067445 T2 HU E067445T2 HU E19722256 A HUE19722256 A HU E19722256A HU E19722256 A HUE19722256 A HU E19722256A HU E067445 T2 HUE067445 T2 HU E067445T2
Authority
HU
Hungary
Prior art keywords
mirikizumab
treatment
ulcerative colitis
ulcerative
colitis
Prior art date
Application number
HUE19722256A
Other languages
English (en)
Hungarian (hu)
Inventor
James Benedict Canavan
Stuart William Friedrich
Kathryn Ann Krueger
Catherine Milch
Jay Lawrence Tuttle
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HUE067445T2 publication Critical patent/HUE067445T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HUE19722256A 2018-03-30 2019-03-28 Mirikizumab fekélyes vastagbélgyulladás kezelésében HUE067445T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862650314P 2018-03-30 2018-03-30

Publications (1)

Publication Number Publication Date
HUE067445T2 true HUE067445T2 (hu) 2024-10-28

Family

ID=66429483

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE19722256A HUE067445T2 (hu) 2018-03-30 2019-03-28 Mirikizumab fekélyes vastagbélgyulladás kezelésében

Country Status (29)

Country Link
US (2) US12152072B2 (enExample)
EP (2) EP4327866B1 (enExample)
JP (4) JP7119114B2 (enExample)
KR (1) KR102552693B1 (enExample)
CN (1) CN111936165A (enExample)
AU (2) AU2019243283C1 (enExample)
BR (1) BR112020018099A2 (enExample)
CA (1) CA3095297A1 (enExample)
DK (1) DK3773715T3 (enExample)
EA (1) EA202091989A1 (enExample)
ES (1) ES2983809T3 (enExample)
FI (1) FI3773715T3 (enExample)
HR (1) HRP20240904T1 (enExample)
HU (1) HUE067445T2 (enExample)
IL (2) IL277514B2 (enExample)
LT (1) LT3773715T (enExample)
MA (1) MA52216B1 (enExample)
MD (1) MD3773715T2 (enExample)
MX (1) MX2020010269A (enExample)
MY (1) MY202368A (enExample)
PL (1) PL3773715T3 (enExample)
PT (1) PT3773715T (enExample)
RS (1) RS65661B1 (enExample)
SG (1) SG11202009526RA (enExample)
SI (1) SI3773715T1 (enExample)
TW (2) TWI837532B (enExample)
UA (1) UA128578C2 (enExample)
WO (1) WO2019191464A1 (enExample)
ZA (1) ZA202005388B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113874073A (zh) 2019-05-23 2021-12-31 詹森生物科技公司 用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法
US20210253690A1 (en) * 2020-02-14 2021-08-19 Janssen Biotech, Inc. Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody
CN115768466A (zh) 2020-05-21 2023-03-07 詹森生物科技公司 用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法
JP7423815B2 (ja) * 2020-10-20 2024-01-29 セトラスホールディングス株式会社 治験管理装置、治験管理方法、治験管理プログラム及び治験管理システム
BR112023013444A2 (pt) * 2021-01-06 2024-01-23 Abbvie Deutschland Métodos para tratar doença de crohn e colite ulcerativa
KR20240012469A (ko) * 2021-05-20 2024-01-29 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용요법으로 염증성 장질환을 치료하는 방법
CA3219846A1 (en) * 2021-05-28 2022-12-01 Venkatesh Krishnan Anti-il-23p19 antibody regulation of genes involved in ulcerative colitis
EP4623001A1 (en) * 2022-11-22 2025-10-01 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
AU2024236477A1 (en) 2023-03-10 2025-09-11 Eli Lilly And Company Methods of treating ulcerative colitis
TW202500185A (zh) * 2023-06-16 2025-01-01 大陸商信達生物製藥(蘇州)有限公司 重組抗白介素23p19亞基抗體在治療炎症性腸病中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3501537A1 (en) * 2005-06-30 2019-06-26 Janssen Biotech, Inc. Anti-il23 antibodies, compositions, methods and uses
JP5193881B2 (ja) 2005-12-29 2013-05-08 セントカー・インコーポレーテツド ヒト抗il−23抗体、組成物、方法および用途
BRPI0807710B1 (pt) 2007-02-23 2021-12-14 Merck Sharp & Dohme Corp Anticorpos que se ligam a il-23p19 e il-23 humana, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira microbiana, método de produção de um polipeptídeo e composição farmacêutica
US20110212104A1 (en) * 2008-11-03 2011-09-01 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
PT2635601T (pt) * 2010-11-04 2016-09-27 Boehringer Ingelheim Int Anticorpos anti-il-23
JOP20140049B1 (ar) 2013-03-08 2021-08-17 Lilly Co Eli أجسام مضادة ترتبط بـ il-23
US20170002060A1 (en) * 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
US20190269757A1 (en) * 2018-03-05 2019-09-05 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody

Also Published As

Publication number Publication date
JP2025020134A (ja) 2025-02-12
US12152072B2 (en) 2024-11-26
AU2019243283A1 (en) 2020-09-24
US20210032325A1 (en) 2021-02-04
JP7119114B2 (ja) 2022-08-16
AU2019243283B2 (en) 2023-07-27
IL277514B2 (en) 2024-11-01
US20250034243A1 (en) 2025-01-30
EP3773715A1 (en) 2021-02-17
HRP20240904T1 (hr) 2024-10-11
KR102552693B1 (ko) 2023-07-07
SG11202009526RA (en) 2020-10-29
EA202091989A1 (ru) 2021-01-13
JP2022169562A (ja) 2022-11-09
FI3773715T3 (fi) 2024-05-30
KR20200128101A (ko) 2020-11-11
MD3773715T2 (ro) 2024-10-31
IL312807B2 (en) 2025-06-01
JP2021517156A (ja) 2021-07-15
EP3773715B1 (en) 2024-05-08
TWI744617B (zh) 2021-11-01
EP4327866A3 (en) 2024-03-20
JP7331219B2 (ja) 2023-08-22
JP7571225B2 (ja) 2024-10-22
CN111936165A (zh) 2020-11-13
IL277514B1 (en) 2024-07-01
MX2020010269A (es) 2020-11-06
MY202368A (en) 2024-04-24
UA128578C2 (uk) 2024-08-21
AU2023248103A1 (en) 2023-11-09
PL3773715T3 (pl) 2024-08-19
IL277514A (en) 2020-11-30
PT3773715T (pt) 2024-05-27
NZ767902A (en) 2024-05-31
SI3773715T1 (sl) 2024-06-28
LT3773715T (lt) 2024-06-25
TW202206104A (zh) 2022-02-16
EP4327866A2 (en) 2024-02-28
EP4327866B1 (en) 2025-12-10
MA52216B1 (fr) 2024-07-31
IL312807B1 (en) 2025-02-01
RS65661B1 (sr) 2024-07-31
TW201946657A (zh) 2019-12-16
JP2023166388A (ja) 2023-11-21
ES2983809T3 (es) 2024-10-24
AU2019243283C1 (en) 2024-05-02
CA3095297A1 (en) 2019-10-03
DK3773715T3 (da) 2024-05-27
BR112020018099A2 (pt) 2020-12-22
MA52216A (fr) 2021-02-17
WO2019191464A1 (en) 2019-10-03
ZA202005388B (en) 2025-05-28
TWI837532B (zh) 2024-04-01
IL312807A (en) 2024-07-01

Similar Documents

Publication Publication Date Title
SI3773715T1 (sl) Mirikizumab pri zdravljenju ulcerativnega kolitisa
IL269354A (en) Compounds useful in the treatment or prevention of prmt5-mediated disorder
GB201614522D0 (en) Use of cannabinoids in the treatment of multiple myeloma
GB201411496D0 (en) Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy
GB201400442D0 (en) Compositions for use in the treatment of ulcerative colitis
IL268210A (en) Use of gaboxadol in the treatment of tinnitus
PL3331610T3 (pl) Środki do zastosowania w leczeniu glejaka
IL272962A (en) Use of gaboksadol for the treatment of anesthesia
IL279917A (en) Treating ulcerative colitis with brazikumab
PL3580182T3 (pl) Uzdatnianie wody
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
IL269121A (en) Usl-311 for use in the treatment of cancer
IL259205B (en) Glycolipid compounds and their uses in the treatment of tumors
SI3548006T1 (sl) Sestava za uporabo pri zdravljenju črevesnih sprememb
SG2013079843A (en) Use of tocotrienols in the treatment or prevention of ulcerative colitis
GB201609851D0 (en) Water treatment
GB201617715D0 (en) Methods for the treatment and prevention of ebola
ZA201703047B (en) The treatment of water
ZA201804726B (en) Water treatment facility
IL255001B (en) Clonidine and/or clonidine derivatives for use in the prevention and/or treatment of negative side effects of chemotherapy
ZA201706977B (en) Water treatment
ZA201702594B (en) Water treatment
GB201614103D0 (en) Water treatment
HK40000513A (en) Formulations and methods for treating ulcerative colitis
GB201617591D0 (en) Methods for the treatment and prevention of ebola